Professor Trevor Graham
MSc, MRes, PhD
Professor of Cancer Evolution
Deputy Centre Lead, Group Leader, Research Theme Lead
TwitterResearch Focus
My lab measures the patterns of clonal evolution that define carcinogenesis and develops novel mathematical tools for analysis and prediction. By characterising tumour evolution, we aim to find better ways to determine prognosis and more effective ways to treat cancers.
Key Publications
Quantification of subclonal selection in cancer from bulk sequencing data. Nature Genetics (2018) 50(6) 895-903. PMID: 29808029
Identification of neutral tumor evolution across cancer types. Nature Genetics (2016) 44, 238-244. PMID: 26780609
The effects of mutational processes and selection on driver mutations across cancer types. Nature Communications (2018) 9(1) 1857. PMID: 29748584
Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. Nature Communications (2017), 8(1) 1998. PMID: 29222441
Major Funding
- 2018-2023- NIH, Arizona Centre for Cancer Evolution (ACE) Cancer Systems Biology Centre, direct funding of ~$800k of $8M total
- 2017-2022- Wellcome Trust, Evolutionary predictions in colorectal cancer (EPICC), ~£1.3m
- 2015-2021- Cancer Research UK, Career Development Award: Quantification of human colorectal cancer evolution: initiation, progression, metastasis and response to treatment, £1M
Other Activities
- Faculty of gastrointestinal cancer section of F1000.com
- Evolution lead for the colorectal cancer domain (GeCIP) of Genomics England
- Member of Critical Gaps in Bowel Cancer Research working group
Research
The central themes of my lab are:
- Characterising intra-tumour heterogeneity and using it to predict prognosis
- Understanding and predicting the evolution of premalignant disease.
- Understanding how the clonal structure of tissues (particularly in the GI tract) shape patterns of somatic evolution.
The major tools of the lab are genomics, bioinformatics, histopathology and mathematical modelling.
Other Activities
- Faculty of gastrointestinal cancer section of F1000.com
- Evolution lead for the colorectal cancer domain (GeCIP) of Genomics England
- Member of Critical Gaps in Bowel Cancer Research working group
Major Funding
- 2018-2023- NIH, Arizona Centre for Cancer Evolution (ACE) Cancer Systems Biology Centre, direct funding of ~$800k of $8M total
- 2018-2021- Cancer Research UK, Early detection of colorectal cancer risk in patients with inflammatory bowel disease ~£0.5M
- 2017-2019- Bowel and Cancer Research, The epigenetic basis of exceptional survival in metastatic colon cancer, £50k
- 2017-2022- Wellcome Trust, Evolutionary predictions in colorectal cancer (EPICC), ~£1.3m
- 2015-2018- Barts Charity, Large Project Grant: Derivation of evolutionary biomarkers for cancer risk prediction in Ulcerative Colitis, £465k
- 2015-2021- Cancer Research UK, Career Development Award: Quantification of human colorectal cancer evolution: initiation, progression, metastasis and response to treatment, £1M
Recent Publications
Author Correction: The effects of mutational processes and selection on driver mutations across cancer types (Nature Communications, (2018), 9, 1, (1857), 10.1038/s41467-018-04208-6) Temko D, Tomlinson IPM, Severini S et al. Nature Communications (2020) 11(7)
Measuring single cell divisions in human tissues from multi-region sequencing data Werner B, Case J, Williams MJ et al. Nature Communications (2020) 11(7)
Evolutionary dynamics of neoantigens in growing tumors Lakatos E, Williams MJ, Schenck RO et al. Nature Genetics (2020) 52(7) 1057-1066
Subclonal reconstruction of tumors using machine learning and population genetics Graham T, Caravagna G, Heide T et al. Nature Genetics (2020) 52(1) 898-907
https://www.biorxiv.org/content/10.1101/586560v1
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype Lupo B, Sassi F, Pinnelli M et al. Science Translational Medicine (2020) 12(7)
Navigating the path to distant metastasis Graham TA, Shibata D Nature genetics (2020) 52(7) 642-643
Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma Araf S, Korfi K, Bewicke-Copley F et al. Haematologica (2020) 105(7) E318-E321
Cancer associated fibroblast FAK regulates malignant cell metabolism. Demircioglu F, Wang J, Candido J et al. Nature Communications (2020) 11(1) 1290-1290
https://www.ncbi.nlm.nih.gov/pubmed/32157087
Measuring the distribution of fitness effects in somatic evolution by combining clonal dynamics with dN/dS ratios Williams MJ, Zapata L, Werner B et al. eLife (2020) 9(7)
Author Correction: Resolving genetic heterogeneity in cancer (Nature Reviews Genetics, (2019), 20, 7, (404-416), 10.1038/s41576-019-0114-6) Turajlic S, Sottoriva A, Graham T et al. Nature Reviews Genetics (2020) 21(7) 65
For additional publications, please click hereTeam
Postdoctoral Researchers in this group
Dr William Cross, Dr Marc Williams, Dr Eszter Lakatos, Dr Annie Baker, Dr Maximilian Mossner
PhD Students
Freddie Whiting, Jacob Househam, Calum Gabbutt
Clinical Research Fellows
Anisha Sukha, Ibrahim Al Bakir, Alison Berner
Biography
I originally trained as a mathematician (MSci Mathematics, Imperial College, 2002) before spending time in a cancer genetics lab as part of my interdisciplinary PhD (PhD Mathematical Biology, UCL, 2009). As a postdoc, I worked in Nick Wright's lab at the Cancer Research UK London Research Institute studying clonal expansions in human tissues (2008-2011), and Carlo Maley’s lab at UCSF looking at the pattern of clonal evolution in human cancers (2011-2013).
I joined BCI in September 2013.
Please contact me to discuss opportunities. Further information about my lab can be found here.